1Akarolo-Anthony SN, Ogundiran TO, Adebamowo CA. Emerging breast cancer epidemic : evidence from Africa [ J ]. Breast Cancer Res,2010, 12 Suppl 4 : S8.
2Lehmann BD, Pietenpol JA. Identification and use of bionmrkers in treatment strategies for triple-negative breast cancer subtypes [J]. J Pathol, 2014, 232(2) :142 -150.
3Peng Y. Potential prognostic tumor biomarkers in triple-negative breast carcinoma[ J]. Beijing Da Xue Xue Bao, 2012, 44(5 ) : 666 - 672.
4Criscitiello C, Azim HA, Schouten PC, et al. Understanding the biology of triple-negative breast cancer[ J]. Ann Oncol, 2012,23 Suppl 6 :vil3 - 18.
5Roger P, Sahla ME, Makela S, et al. Decreased expression of estrogen receptor beta protein in proliferative preinvasive mammary tumors [ J ]. Cancer Res, 2001,61 (6) : 2537 - 2541.
6Sugiura H, Toyama T, Hara Y, et al. Expression of estrogen receptor beta wild-type and its variant ERbetacx/beta2 is correlated with better prognosis in breast cancer [ J ]. Jpn J Clin Onco1,2007, 37 ( 11 ) : 820 - 828.
7Iwase H, Ando Y, Ichihara S. Immunohistochemical analysis on biological markers in ductal carcinoma in situ of the breast [ J ]. Breast Cancer, 2001,8(2) :98 - 104.
8Park S, Koo JS, Kim MS, et al. Androgen receptor expression is significantly associated with better outcomes in estrogen receptor- positive breast cancers [ J ]. Ann Oncol, 2011,22 ( 8 ) : 1755 - 1762.
9Gucalp A, Traina TA. Triple-negative breast cancer: role of the androgen receptor [ J ]. Cancer J, 2010,16 ( 1 ) :62 - 65.
10Taneja P, Maglic D, Kai F, et al. Classical and novel prognostic markers for breast cancer and their clinical significance[ J]. Clin Med Insights Oncol, 2010,4 : 15 - 34.
3Li CY, Zhang S, Zhang XB, et al. Clinic pathological and prognostic characheristics of triple-negative breast cancer (TNBC) in Chinese patients: a retrospective study [J]. Asian Pacific Journal of Cancer Prevent, 2013, 14(5): 3779-3784.
4Usatyuk PV, Fu P, Mohan V, et al. Role of c-Met/phos-phatidy- linositol 3-kinase (PI3k)/Akt signaling in hepato-cyte growth factor (HGF)-mediated lamellipodia formation, reactive oxygen species(ROS) generation, and motility of lung endothelial cells[J]. J Bid Chem, 2014, 289(19): 13476-13491.
5Shah YM, Van Den Brink GR. c-Kit as a Novel Potential Therapeutic Target in Colorectal Cancer[J]. Gastroenterology, 2015, 149(3): 534-537.
6Zhao F, Chen Y, Wu Q, et al. Prognostic value of CDII7 in cancer: a meta-analysis[J]. Int J Clin Exp Pathol, 2014, 7(3): 1012-1021.
7Neradil J, Veselska R. Nestin as a marker of cancer stem ceils [J]. Cancer Sci, 2015, 106(7): 803-811.
8Gao N, Xu H, Liu C, et al. Nestin: predicting specific survival factors for breast caner[J]. Tumour Biol, 2014, 350): 1751-1755.
9Zhu Y, Wang Y, Guan B, et al. C-kit and PDGFRA gene mutations in triple negative breast cancer[J]. Int J Clin Exp Pathol, 2014, 7(7): 4280-4285.
10Lehmann BD,Pietenpol JA.Identification and use of biomarkers in treatment strategies for triple-negative breast cancer subtypes[J].J Pathol,2014,232(2):142-150.
